Merck Past Earnings Performance
Past criteria checks 0/6
Merck's earnings have been declining at an average annual rate of -3.8%, while the Pharmaceuticals industry saw earnings growing at 11.4% annually. Revenues have been growing at an average rate of 8.8% per year. Merck's return on equity is 6.2%, and it has net margins of 3.8%.
Key information
-3.8%
Earnings growth rate
-3.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 12.4% |
| Revenue growth rate | 8.8% |
| Return on equity | 6.2% |
| Net Margin | 3.8% |
| Next Earnings Update | 30 Jul 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses BreakdownBeta
How Merck makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 61,403 | 2,306 | 9,838 | 29,459 |
| 31 Dec 23 | 60,115 | 365 | 9,884 | 29,751 |
| 30 Sep 23 | 59,315 | 4,608 | 10,226 | 23,890 |
| 30 Jun 23 | 58,311 | 3,111 | 9,934 | 24,094 |
| 31 Mar 23 | 57,869 | 13,030 | 9,851 | 13,550 |
| 31 Dec 22 | 59,283 | 14,519 | 9,669 | 11,918 |
| 30 Sep 22 | 58,974 | 15,322 | 10,119 | 13,479 |
| 30 Jun 22 | 57,169 | 16,641 | 9,776 | 12,496 |
| 31 Mar 22 | 53,978 | 13,910 | 9,489 | 12,071 |
| 31 Dec 21 | 48,704 | 12,345 | 9,403 | 11,942 |
| 30 Sep 21 | 46,131 | 5,908 | 9,260 | 10,725 |
| 30 Jun 21 | 43,906 | 3,665 | 8,845 | 10,678 |
| 31 Mar 21 | 41,857 | 4,793 | 8,669 | 10,339 |
| 31 Dec 20 | 41,518 | 4,519 | 8,569 | 13,224 |
| 30 Sep 20 | 42,438 | 9,492 | 8,812 | 9,079 |
| 30 Jun 20 | 43,906 | 9,070 | 9,200 | 8,818 |
| 31 Mar 20 | 46,312 | 9,399 | 9,700 | 8,990 |
| 31 Dec 19 | 39,121 | 5,690 | 8,829 | 8,594 |
| 30 Sep 19 | 45,970 | 9,314 | 9,604 | 8,489 |
| 30 Jun 19 | 44,367 | 9,362 | 9,586 | 7,997 |
| 31 Mar 19 | 43,073 | 8,399 | 9,467 | 8,084 |
| 31 Dec 18 | 42,294 | 6,220 | 9,587 | 9,254 |
| 30 Sep 18 | 41,729 | 3,347 | 9,541 | 9,251 |
| 30 Jun 18 | 41,259 | 1,341 | 9,554 | 11,680 |
| 31 Mar 18 | 40,725 | 1,579 | 9,449 | 11,182 |
| 31 Dec 17 | 40,122 | 2,394 | 9,560 | 9,845 |
| 30 Sep 17 | 39,804 | 2,845 | 9,615 | 9,427 |
| 30 Jun 17 | 40,016 | 5,086 | 9,612 | 6,916 |
| 31 Mar 17 | 39,929 | 4,346 | 9,713 | 7,035 |
| 31 Dec 16 | 39,807 | 3,920 | 9,313 | 6,921 |
| 30 Sep 16 | 39,907 | 5,492 | 9,193 | 6,849 |
| 30 Jun 16 | 39,444 | 5,133 | 9,312 | 6,828 |
| 31 Mar 16 | 39,385 | 4,614 | 9,776 | 6,518 |
| 31 Dec 15 | 39,498 | 4,442 | 9,799 | 6,613 |
| 30 Sep 15 | 39,765 | 10,781 | 10,262 | 6,727 |
| 30 Jun 15 | 40,249 | 9,850 | 10,756 | 6,644 |
| 31 Mar 15 | 41,398 | 11,168 | 10,818 | 6,685 |
| 31 Dec 14 | 42,237 | 11,920 | 11,172 | 6,532 |
| 30 Sep 14 | 43,075 | 5,385 | 11,501 | 6,435 |
| 30 Jun 14 | 43,550 | 5,614 | 11,304 | 6,544 |
| 31 Mar 14 | 43,626 | 4,516 | 11,511 | 6,774 |
| 31 Dec 13 | 44,033 | 4,404 | 11,672 | 7,123 |
| 30 Sep 13 | 44,450 | 4,531 | 12,084 | 7,563 |
| 30 Jun 13 | 44,907 | 5,136 | 12,303 | 7,822 |
Quality Earnings: MRK has a large one-off loss of $1.8B impacting its last 12 months of financial results to 31st March, 2024.
Growing Profit Margin: MRK's current net profit margins (3.8%) are lower than last year (22.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MRK's earnings have declined by 3.8% per year over the past 5 years.
Accelerating Growth: MRK's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: MRK had negative earnings growth (-82.3%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (5.2%).
Return on Equity
High ROE: MRK's Return on Equity (6.2%) is considered low.